Skadden is advising BeiGene on a global strategic oncology collaboration with Amgen. In connection with the collaboration, Amgen will acquire a 20.5% stake in BeiGene for $2.7 billion.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates